Study of NEO-201 in Solid Tumors Expansion Cohorts
Non Small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Cervical Cancer · Uterine Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 121 (planned)
- Started
- Jan 18, 2019
- Main results expected
- Jun 17, 2026
- Fully finished
- Nov 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Determine the safety of the combination of NEO-201 with pembrolizumab the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Measured over: 1.5 years
Determine Objective Response Rate (either Complete Response or Partial Response) as determined by RECIST v1.1 guidelines
Measured over: 1.5 years
Determine Progression Free Survival as determined by RECIST v1.1 guidelines
Measured over: 1.5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03476681 · record last updated 2026-06-22 · checked 2026-11-09 15:47 UTC